के सभी प्रकाशन Diksha Pote . पुणे , भारत

Publications

Kidney Stone Market Revenue Analysis, Company Revenue Share, Global Forecast Till 2027


Key Players:

The key players profiled in Kidney stone are Boston Scientific Corporation, Convergent Laser Technologies, DirexGroup, Siemens Healthcare GmbH, C.R. Bard Inc, Cook Medical Inc., Dornier MedTech GmbH, Richard Wolf Medical Instruments Corporation, Olympus Corporation, and Stryker Corporation

Global Kidney stones Market – Overview

Kidney stones are hard mineral deposits inside the kidneys that can cause severe pain and discomfort. The global kidney stone market is growing at a steady pace and it is expected to grow at a CAGR of 4.0% during the forecast period of 2017 - 2022. There are a number of protuberant factors associated with this Global Kidney Stone Market Report. Growing demand for minimally invasive procedures driven by the surging preference of these is one of the major drivers contributing to the market growth. The preference to minimally invasive procedures is driven by their success rate which is 75-100%. Additionally, according to the National Kidney Foundation, it has been found that more than 73 million adults have high blood pressure and 29 million adults are suffering from diabetes which are the major reason for urolithiasis. That being said, continuously recorded and increasing instances of urolithiasis in the adult is leading to the rise in the prevalence of kidney stone disorder across the globe. Another major reason driving the prevalence of how much is a kidney stone worth is population and poor nutrition. According to experts, individuals who are predisposed to hunger and sub-par nutrition are prone to kidney disorders and thus, add to the total global prevalence to a great extent. With such growth factors the market size is expected to reach $3,000 million in 2022 from $2,277.4 in 2016.

Global Kidney stones Market - Competitive Analysis

Globally there are various players operating in this market. With well-established market in the North America region major companies have their home in the region and generate maximum market share. These companies have expanded their operating unit in various other regions as well. Moreover there are other small and medium scale players that generate revenue from local market.

Minimally invasive procedures for the treatment of kidney stones has been the major factor influencing the growth of the market. A majority of industrial competitors involved in this market have been keen on introducing advanced products for minimally invasive procedures. In November 2016, Boston Scientific Corporation introduced Dakota Nitinol Stone Retrieval Device with OpenSure Handle in US and Europe market. This kidney stone retrieval device is designed to allow to release and capture kidney stones of multiple sizes from complex stones as large as 10 millimeters to fragments as small as one millimeter. This product will support the company to imprison its position and resolve a few challenges faced during ureteroscopy procedures. Adding to this in May 2017, Lumenis a well know medical device company launched its New Moses holmium technology in the American Urological Association Annual Meeting. To this technology Dr. Andrew Symes, Consultant Urological Surgeon said “The Moses technology provides a greater sense of control due to minimized retropulsion. This is particularly valuable when dusting large stones in the kidney, but also when dealing with upper ureteric stones”. These advancements are collectively influencing the growth of this market positively.

Furthermore the kidney stone treatment market has turned into a critical factor in the global urology industry. Through extensive research it is found out that the market players have adopted the strategy of acquisitions in the market. In 2016 Boston Scientific acquired Distal Access, LLC with its product line gynecology and urology. Distal Access a U.S. based company involved in manufacturing minimal invasive devices. This acquisition will help Boston Scientific reduce the pressure of developing minimal invasive devices. The gynecology and urology devices manufactured by Distal Access will be integrated into the Boston Scientific urology and pelvic health business. Be that as it may, in February 2016, Stryker Corp announced a definitive agreement to acquire Synergetics USA, Inc.'s Neuro Portfolio. This strategic step of the company to acquire all the neurological product portfolio of Synergetics USA, Inc.'s will strengthen the company’s presence in the field of Neurology, adding to their global footprint. In a similar distribution agreement by the Olympus Corp of The Americas with Arc Medical Design, will facilitate and improve the distribution strength of the partner companies in the U.S. and Canada, resulting in improving their worldwide sales. There are various others players involved in following this strategy of acquisition that is helping in the growth of revenue of the companies and in turn influencing the growth of the market.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America

Show more
0
1

Liquid Biopsy Market Revenue Analysis, Company Revenue Share, Global Forecast Till 2027


Market Highlights

Biopsy involves extracting a sample of tissue and testing it for the presence of diseases especially cancer. Traditional tissue biopsy is a painful technique and also has a high rate of false results. Moreover the technique is costly, time consuming and not applicable for extracting samples such as those close to vital organs such as heart. Liquid biopsy overcomes these problems of tissue biopsy by using biomarkers present in samples such as blood, urine etc. and thus is a comparatively non-invasive technique. Liquid biopsy also provides greater information about the sample which is real time. The real time data can be used for monitoring and thereby determining the treatment for diseases such as cancer. The greater sensitivity of tissue biopsy coupled with the development of sophisticated detectors with extremely low detection rates have enabled the early detection of diseases which is the holy grail of cancer.

Other market drivers for the liquid biopsy market are rising rates of cancer, growing investment in research and development, collaborations between companies and public organizations, rise in geriatric population, rising expenditure on health etc. The factors which are inhibiting the growth of the market includes the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. However, not all cancer patients benefit from early detection as some cancer types such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.

Also the technique is not applicable to all types of cancer as some cancers such as brain cancer and prostate cancer may lie dormant for many years, and thus are either undetectable or detected very late which robs liquid biopsy of its advantages. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.

Major Players of Global liquid biopsy market:

The major participants of this liquid biopsy companies are: Guardant Health, Inc., Trovagene, Inc., RainDance Technologies, Inc., Agena Bioscience Inc. Inc., Admera Health, Biocept, Inc., Circulogene Theranostics, Inivata Ltd., SAGA Diagnostics AB, Exosome Diagnostics and others.

Segmentation:

Global Liquid Biopsy Market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centres and others.

Regional Analysis:

Depending on geographic region, Liquid biopsy market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America is the largest market for Liquid biopsy. Europe is the second-largest market for liquid biopsy. The developing regions market such as Asia pacific region and Middle East & Africa however is rising much faster.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America

Show more
0
1

Optical Biometry Devices Market Revenue Analysis, Company Revenue Share, Global Forecast Till 2027


Market Highlights

The global optical biometry devices market size accounted for USD 275.0 million in 2018 and is projected to register a CAGR of 5.6% over the forecast period. Optical biometry, also known as ophthalmic biometry, is the current standard for intraocular lens (IOL) power calculations in clinical practice. This is used to measure the anatomical characteristics of the eye. Optical biometry by using partial coherence interferometry (PCI) is more accurate, easy to perform, non-invasive, and comfortable for the patient. Factors characterizing the market growth are worldwide increasing geriatric population, increased efficiency of optical biometry over ultrasound A-scans, growing awareness about eye care, rising older population, and a surge in the number of cataract and refractive surgeries. A data published by the World Health Organization (WHO), globally, approximately 1.3 billion people live with some form of vision impairment at present. On the contrary, lack of skilled personnel and high cost of optical biometry devices are anticipated to hinder the market growth over the forecast period.

Next-generation optical biometry devices reduce the undetected poor fixations by the optical ultrasound biometry devices. Furthermore, these devices are highly efficient and fast, eliminating manual errors from traditional biometry devices. For instance, Pentacam AXL is used with a single measuring operation. It has a comprehensive biometry for intraocular lens (IOL) database and provides a well-targeted screening process for eyes.

Key Players

Few of the leading players in the global optical biometry devices market are Carl Zeiss AG, Bausch & Lomb Incorporated, Haag-Streit AG, NIDEK CO., LTD., Topcon Corporation, Welch Allyn, Inc., Heine Optotechnik GmbH & Co. KG, Tomey Corporation, AMETEK, Inc., Optovue, Incorporated, Leica Microsystems GmbH, and CENTERVUE S.p.A.

Segmentation

The global Optical Biometry Devices Market Size has been segmented into product and end user.

By product, the market has been segmented into swept-source optical coherence tomography (SSOCT)-based biometers, partial coherence interferometry (PCI)-based biometers, and optical low coherence reflectometry (OLCR)-based biometers. The swept-source optical coherence tomography (SSOCT)-based biometers segment held the largest market share in 2018 due to its features such as multiple measurements in a single process, fast data acquisition, and the capability to overcome ocular opacities and superior wavelength. The swept source technology provides clear advantages over the partial coherent interferometry, including the ability to measure the axial length along six different axes and extremely rapid data acquisition.

The partial coherence interferometry-based biometers segment is expected to register the fastest CAGR over the forecast period as optical biometry using partial coherence laser interferometry (PCLI) offers advantages in accuracy and reproducibility of axial length (AL) determination as well as are more comfortable for the patient and the investigator as compared to conventional ultrasonic biometry.

Based on end user, the optical biometry market has been classified into hospitals, ophthalmic clinics, and others. A gradual rise in the number of government and private hospitals in emerging countries such as China and India along with increase in the adoption of optical biometry devices in hospitals is expected to support the dominance the hospital’s segment. In terms of value, the US is holding comparatively larger share (hospitals) of the market; however, decreasing number of hospitals in recent years is limiting the market growth. According to the American Hospital Association (AHA), currently, total number of hospitals in the US are 6,210.

The ophthalmic clinics segment would register comparatively higher CAGR throughout the forecast period owing to increasing density of ophthalmology clinics in developed and developing markets contributing to rising adoption of next generation optical biometry devices.

Regional Segmentation

The global optical biometry devices market has been categorized on the basis of region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America

Show more
0
1
Show more